Table 1.

Association between CYP7A1 SNPs and clinical phenotypes in the OSU CAD cohort (a) and CATHGEN cohort (b).

		rs3808607 GT+TT vs GG	rs9297994 AG+GG vs AA	rs3808607 + rs92979941
Total cholesterol n=396	Beta	−9.19	0.85	−16.59
	P value	0.12	0.86	0.05
LDL level n=383	Beta	−3.79	3.67	−13
	P value	0.41	0.30	0.04
HDL level n=396	Beta	−2.61	0.73	3.32
	P value	0.08	0.53	0.11
Triglycerides n=395	Beta	−7.09	−25.51	−45.89
	P value	0.76	0.16	0.16
Reaching cholesterol reducing target n=196	Odds ratio (95% CI)	1.12 (0.48–2.57)	0.94 (0.50–1.78)	0.43 (0.18–0.99)
	P value	0.80	0.85	0.05
MI n=477	Odds ratio (95% CI)	0.85 (0.35–2.05)	0.71 (0.35–1.46)	0.65 (0.27–1.58)
	P value	0.71	0.36	0.342
Hypertension n=477	Odds ratio (95% CI)	0.89 (0.44–1.79)	1.00 (0.56–1.77)	0.93 (0.46–1.88)
	P value	0.73	0.99	0.83
Diabetes n=477	Odds ratio (95% CI)	1.26 (0.62–2.56)	0.83 (0.46–1.50)	0.86 (0.42–1.75)
	P value	0.52	0.54	0.67

		rs3808607 GT+TT vs GG	rs9297994 AG+GG vs AA	rs3808607 + rs92979941
CADINDEX2 n=1140	Odds ratio (95% CI)	1.18 (0.86–1.60)	1.15 (0.89–1.48)	0.54 (0.40–0.73)
	P value	0.31	0.29	<0.0001
MI n=1140	Odds ratio (95% CI)	0.90 (0.63–1.29)	1.29 (0.96–1.73)	0.56 (0.40–0.79)
	P value	0.56	0.10	0.001
Diabetes n=1140	Odds ratio (95% CI)	0.87 (0.63–1.20)	0.78 (0.59–1.02)	1.48 (1.09–2.01)
	P value	0.41	0.07	0.01
Hypertension n=1140	Odds ratio (95% CI)	0.71 (0.50–0.99)	0.99 (0.76–1.29)	1.88 (1.33–2.64)
	P value	0.05	0.94	<0.0001
Hypercholesterolemia n=1140	Odds ratio (95% CI)	0.99 (0.72–1.36)	1.14 (0.88–1.48)	0.84 (0.62–1.14)
	P value	0.95	0.33	0.25
Death n=1139	Odds ratio (95% CI)	1.03 (0.73–1.47)	1.02 (0.77–1.36)	0.79 (0.55–1.12)
	P value	0.85	0.87	0.18

¹Comparing number of reduced activity alleles 0+1 vs 2 or more

²CADINDEX comparing subjects with CADINDEX <23 vs CADINDEX >23 (clinically significant).